Oral Abstract Session:
28. New Considerations in C. difficile Prevention and Treatment
Thursday, October 3, 2013: 8:30 AM-10:00 AM
Room: The Moscone Center: 300

Learning Objectives:

-

Tracks: Adult ID, Epidemiology and Infection Control

Moderators:  Charlesnika Evans, PhD MPH, Department of Veterans Affairs and Erik Dubberke, MD, MSPh, Washington University School of Medicine

Presentations:

8:30 AM
85
Calcium Channel Blockers and Clostridium difficile Risk: a UK Population-based Nested Case-control Study
Oluwakayode Oke, MD, MSc ; Moses Katbi, MD, MSc ; Richard Puleston, MBChB, DCH, MRCGP, MRCP, MBA, MPH, FFPH

8:42 AM
86
A Randomized Trial of Soap and Water Hand Wash Versus Alcohol Hand Rub for Removal of Clostridium difficile Spores from Hands of Infected or Colonized Patients
Sirisha Kundrapu, M.D. ; Venkata C.K. Sunkesula, M.D., M.S ; Abhishek Deshpande, M.D., Ph.D. ; Curtis J. Donskey, MD

8:54 AM
87
Severe Clostridium difficile Infection in Children
Jonathan Crews, MD ; Hoonmo L. Koo, MD ; Zhi-Dong Jiang, MD, PhD ; Jeffrey Starke, MD, FIDSA ; Herbert Dupont, MD, FIDSA

9:06 AM
88
Reduction in Clostridium difficile infections among neurosurgical patients through the discontinuation of antimicrobial prophylaxis for the duration that an external ventricular drain remains in place
Timothy H. Dellit, MD ; Jeannie D. Chan, PharmD, MPH ; Charlotte Fulton, RN MHA ; Ronald Pergamit, MPA ; Elizabeth Mc Namara, RN MN ; Louis Kim, MD ; Richard Ellenbogen, MD ; John B. Lynch, MD MPH

9:18 AM
89
Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI)
Thomas Louie, M D ; Kris Cannon, BSc, MBT ; Heidi O'grady, PhD ; Kaiyu Wu, PhD ; Linda Ward, MLT

9:30 AM
90
Fecal Microbial Transplantation: Highly Effective Treatment for Severe Clostridium difficile Infection
Linda Bobo, MD, PhD ; Erica Kaufman, MD ; Diana Biggs, MT, ASCP, SM

9:42 AM
91
Household surveillance of patients with recurrent Clostridium difficile infection (CDI)
Megan K. Shaughnessy, MD ; Aleh Bobr, MD ; Michael Sadowsky, PhD ; Alexander Khoruts, MD ; James R. Johnson, MD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

C. Evans, None

E. Dubberke, Merk: Consultant and Investigator, Consulting fee and Research support
Viropharma : Investigator, Research support
Optimer: Consultant and Investigator, Consulting fee and Research support
Pfizer : Consultant, Consulting fee
Sanofi Pasteur: Investigator, Research support
bioMerieux: Consultant, Consulting fee

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.